drugset
drugset / Trial / NCT00366678

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

NCT00366678 ↗

Phase 3 Completed 613 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in France.

Timeline

Start
2006-10
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prevnar 13 Vaccine 0.5 ml —
Background DTP-HB-Hib vaccine Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.